DivestmentJun 30, 2026, 04:41 PM
Advanced Biomed Sells Taiwan Subsidiary for $490,000
AI Summary
Advanced Biomed Inc. has entered into a Share Purchase Agreement to sell its wholly-owned subsidiary, Advanced Biomed Inc. (Taiwan), to an unrelated third party. The sale of the biomedical research and development operations, including the A+PerfusC platform, is for an aggregate purchase price of US$490,000. The transaction is anticipated to close within three months, while the company will continue to operate its remaining AI-focused businesses.
Key Highlights
- Advanced Biomed Inc. agreed to sell 100% of its Taiwan subsidiary.
- The aggregate purchase price for the subsidiary is US$490,000.
- The transaction is expected to close within three months from June 30, 2026.
- The Taiwan Subsidiary conducted biomedical R&D, including the A+PerfusC platform.
- Advanced Biomed will continue its AI-focused operations through Acellent Technologies.
Price Impact
More from ADVB